322 related articles for article (PubMed ID: 21288472)
1. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.
Chung YC; Bok E; Huh SH; Park JY; Yoon SH; Kim SR; Kim YS; Maeng S; Park SH; Jin BK
J Immunol; 2011 Dec; 187(12):6508-17. PubMed ID: 22079984
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
[TBL] [Abstract][Full Text] [Related]
4. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease.
Huh SH; Chung YC; Piao Y; Jin MY; Son HJ; Yoon NS; Hong JY; Pak YK; Kim YS; Hong JK; Hwang O; Jin BK
J Immunol; 2011 Jul; 187(2):960-9. PubMed ID: 21685323
[TBL] [Abstract][Full Text] [Related]
5. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity.
Zhang D; Hu X; Wei SJ; Liu J; Gao H; Qian L; Wilson B; Liu G; Hong JS
J Neuroinflammation; 2008 May; 5():21. PubMed ID: 18507839
[TBL] [Abstract][Full Text] [Related]
6. Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease.
Chung YC; Baek JY; Kim SR; Ko HW; Bok E; Shin WH; Won SY; Jin BK
Exp Mol Med; 2017 Mar; 49(3):e298. PubMed ID: 28255166
[TBL] [Abstract][Full Text] [Related]
7. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Chung YC; Kim SR; Jin BK
J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
[TBL] [Abstract][Full Text] [Related]
9. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
[TBL] [Abstract][Full Text] [Related]
10. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress.
Chung ES; Chung YC; Bok E; Baik HH; Park ES; Park JY; Yoon SH; Jin BK
Brain Res; 2010 Dec; 1363():143-50. PubMed ID: 20858471
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.
Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW
J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263
[TBL] [Abstract][Full Text] [Related]
12. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
[TBL] [Abstract][Full Text] [Related]
14. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
Delgado M; Ganea D
FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
[TBL] [Abstract][Full Text] [Related]
16. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
17. FTY720 Inhibits MPP
Yao S; Li L; Sun X; Hua J; Zhang K; Hao L; Liu L; Shi D; Zhou H
J Neuroimmune Pharmacol; 2019 Sep; 14(3):478-492. PubMed ID: 31069623
[TBL] [Abstract][Full Text] [Related]
18. Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease.
Kim KI; Chung YC; Jin BK
Mediators Inflamm; 2018; 2018():4591289. PubMed ID: 30692871
[TBL] [Abstract][Full Text] [Related]
19. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
20. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
